Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Boston Scientific unveils results from renal stent study

Boston Scientific : 04 May, 2007  (New Product)
Boston Scientific has revealed two year results from the Renaissance study that was designed to evaluate the safety and effectiveness of the company's Express SD Renal Stent in hypertensive patients with atherosclerotic renal artery stenosis (RAS).
The Express SD Renal Stent (Ref 1) is designed for hypertensive patients with atherosclerotic renal artery stenosis (RAS).

Results were presented during a podium discussion at the All That Jazz conference in New Orleans, USA, by Michael R Jaff, DO, assistant professor of medicine at Harvard Medical School and Medical Director of the Vascular Ultrasound Core Laboratory, Massachusetts General Hospital.

All That Jazz is a scientific meeting for Interventional Cardiologists, Radiologists and Vascular Surgeons.

Renaissance is a prospective, single-arm, multi-centre study involving 100 patients in 14 sites in the USA.

All patients had a single, de novo RAS ( less than or equal to 70 percent).

The primary endpoint of the study was restenosis, or the re-narrowing of a previously stented vessel, at nine months.

The primary nine month Duplex Ultrasound (DUS) endpoint and one year follow-up have been previously reported; the two year clinical and DUS data were reported by Dr Jaff at All That Jazz.

Renaissance is the first study to evaluate DUS as a reliable non-invasive method for surveillance of restenosis with persistent accuracy through two year follow-up.

A total of 117 atherosclerotic aorto-ostial lesions in 100 subjects were analysed; 93 percent and 90 percent of patients were available for nine month and two year clinical follow-up, respectively.

High technical and procedural success rates (99 percent) were achieved with excellent concordance (87 percent) between renal artery DUS and angiography for restenosis.

The binary nine month restenosis rate was 21.3 percent.

Significant improvement in systolic blood pressure compared to baseline was noted at nine months which was maintained through two years (p=0.002).

Safety results at two years were reported with an aggregate Major Adverse Event (MAE) rate of 15.9 percent and with no instances of Stent thrombosis.

The nine month and two year target lesion revascularisation rates (TLR) were 8.1 percent and 14 percent respectively; no MAE related deaths, or progression to renal replacement therapy were reported through the two year follow-up period.

Two significant embolic events were reported prior to nine months.

'The two year Renaissance data are very powerful', said Dr Jaff.

'We finally have prospective multi-centre data supporting the durability of renal artery stents.

'The nine month data revealed excellent correlation between duplex ultrasonography and contrast arteriography.

'The two year data revealed no significant loss of patency between nine months and two years, paralleled by the persistent reduction in blood pressure and avoidance of renal replacement therapy'.

'The release of the two year Renaissance results is an exciting step for the Boston Scientific renal programme', said John Pedersen, president of Boston Scientific's Peripheral Interventions business.

'The Renaissance results have been submitted to the Food and Drug
Administration seeking US approval for indication of the Express SD Renal Stent for use in the renal arteries'.

Renal artery disease is the narrowing of the blood supply to the kidneys due to atherosclerosis, or the formation of plaque within the arteries.

When the kidneys have a normal blood supply, they filter toxins from the blood and help to keep blood pressure in the normal range.

Renal artery disease may lead to high blood pressure or poor kidney function.
Renal artery disease can be treated surgically or less invasively via angioplasty (placement of a balloon at the site of the lesion).

The balloon is inserted through a small incision in the groin and fed through the artery on a Catheter until it is positioned at the site of the blockage.

The balloon is inflated, compressing the plaque against the walls of the artery, and then removed.

Re-narrowing of the arteries is common with this treatment method, however, leading to the study of stenting as a treatment option.

A Stent is an expandable metal mesh tube that remains in the artery after the removal of the balloon that supports the vessel wall to maintain blood flow through the newly opened vessel.

Ref 1 - The Express SD Renal Stent is an Investigational Device in the United States.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo